

Hadron Therapy Workshop: status and perspectives, plans for next generation facilities 18-19 October 2024

Oct 18, 2024, 8:00 AM → Oct 19, 2024, 11:30 PM Europe/Zurich

Zoom

Carbon Programme in MedAustron



MedAustron

Piero Fossati

Scientific Director

MedAustron Ion Therapy Centre

&

**Professor of Radiation Oncology
Karl Landsteiner University of Health Sciences**




Carbon Why?

- Radioresistant histology
- Early in field recurrence after adequate dose
- Sharper penumbra

RADIORESISTENT HISTOLOGY

1. Sarcoma
2. Non SCC H&N Cancer
3. Kidney cancer
4. High risk prostate cancer ?
5. Local recurrence of rectal adenocarcinoma

HEAD AND NECK



Male 43 YO

Initial symptom : closed nose

Diagnosis

Adenoid cystic carcinoma
cT4b cN0

Prescription:


exclusive CIRT

4.1 Gy RBE x 9 to PTV1
(36.9 Gy RBE)


4.3 Gy RBE x 7 to PTV2
(30.1 Gy RBE)

Total dose 67 Gy RBE in
16 fr in 4 weeks



Dose distribution




Response at 12 Mo.



- HEMI MAXILLECTOMY 10/2019
- ACC, post. margin positive
- Perineural involvement
- PT4 N0 M0
- Post-op MRI: perineural invasion including Meckel's cave





Prescription	
PTV3	74 Gy(RBE)
PTV2	68 Gy(RBE)
PTV1	50 Gy(RBE)

- PTV1 = Protons, 50 Gy (RBE) / 25 x 2 Gy (RBE) fractions
- PTV2 = Carbons, sequential boost 6 Gy (RBE)/2 x 3 Gy (RBE) fractions
- PTV3 = Carbons, sequential boost 18 Gy (RBE) / 6 x 3 Gy (RBE)
- **Total cumulation dose:**
74 Gy (RBE) at 2 and 3 Gy (RBE) per fractions

GERMANY


JAPAN

WORLD CUP
2022

VS



TRYING TO GET THE BEST OF BOTH WORLDS



- ACC of the base of tongue
- Bulky GTV (118 ml)
- Macroscopic nerve infiltration
- Non negligible risk of lymph node mets

- PTV1 = Protons, 30 Gy (RBE) / 15 x 2 Gy (RBE) fractions
- PTV1 = Carbons, 18 Gy (RBE) / 6 x 3 Gy (RBE) fractions
- PTV2 = Carbons, sequential boost 6 Gy (RBE)/2 x 3 Gy (RBE) fractions
- PTV3 = Carbons, sequential boost 18 Gy (RBE) / 6 x 3 Gy (RBE)

Carbon How?

- Optimize with LEM, check with MKM, iterate until both RBE models are good enough
- Be mindful of LET

Sacral Chordoma


One RBE model is not enough

Target volume	n	d LEM-I / mMKM	D LEM-I / mMKM	Total D LEM-I / mMKM
PTV1	9	4.6	41.4	37.8
PTV2	7	4.6	32.2	73.6

OARs constraints:

OARs	LEM-I constraint	mMKM constraint
Recto-sigmoid colon	D 1 cc < 66 Gy RBE D 5 cc < 60 Gy RBE	D 1 cc < 60 Gy RBE D 5 cc < 54 Gy RBE
Urinary bladder	D 1 cc < 66 Gy RBE D 50 cc < 50 Gy RBE	Not used
Small bowel	D 0.1cc < 45 Gy RBE D 1cc < 40 Gy RBE	D 0.1cc < 40 Gy RBE D 1cc < 30 Gy RBE
Cauda Equina	D 0.1 cc < 66 Gy RBE	D 0.1 cc < 60 Gy RBE
Nerve roots inside CTV2	D2% < 73 Gy RBE (avoid hot spots)	D2% < 66 Gy RBE (avoid hot spots)
Nerve roots outside CTV2	D5% < 69 Gy RBE	D5% < 62 Gy

Planning / PLAN EVALUATION 3: SUM PLAN



Planning / PLAN EVALUATION 5: HOT SPOT IN 1


BEAMSET

RED 98%

YELLOW 95%

BLUE 102%

Green 103%



Planning TARGET COVERAGE



RED 98% of LEM

YELLOW 95% of
LEM

GREEN 98% of

MKM


BLUE 95% of MKM



Planning / OAR rectum





Treatment planning : LET distribution




LETd Redistribution | central portion of GTV

Distal patching → Redistribution of high LETd component from periphery to the center of GTV




Sharper penumbra ?



420 Carbon ion Treatments

JUL 2018 – Nov 2023



Female 81 YO

RCC operated, M1 (skull) at diagnosis

Previous RT 50 Gy with photons

Diagnosis


Symptomatic progression of previously irradiated skull metastasis from renal cancer

After 2 years SD with systemic therapy

Prescription:


exclusive CIRT

4.6 Gy RBE x 16 (73.6 Gy RBE)



**CIRT
Dose distribution**

Response at 10 Mo.




Toxicity at 18 Mo:

Complete resolution of diplopia


RT induced Tox G0 (no CNS toxicity)

**Unfortunately at 18 local PD of the falx nodule
(neurosurgery is planned in 2 weeks)**




CIRT AND PEDIATRICS ?

- Osteosarcoma



- Sarcoma recurrences



DANKE FÜR IHRE AUFMERKSAMKEIT

